Purple Biotech (PPBT) Competitors $0.56 -0.01 (-0.96%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. NKGN, ALZN, CAPS, CDIO, VIVS, ACXP, PMCB, ENSC, SBFM, and PLRZShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include NKGen Biotech (NKGN), Alzamend Neuro (ALZN), Capstone Therapeutics (CAPS), Cardio Diagnostics (CDIO), VivoSim Labs (VIVS), Acurx Pharmaceuticals (ACXP), Nuvilex (PMCB), Ensysce Biosciences (ENSC), Sunshine Biopharma (SBFM), and Polyrizon (PLRZ). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors NKGen Biotech Alzamend Neuro Capstone Therapeutics Cardio Diagnostics VivoSim Labs Acurx Pharmaceuticals Nuvilex Ensysce Biosciences Sunshine Biopharma Polyrizon NKGen Biotech (NYSE:NKGN) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Do analysts rate NKGN or PPBT? Purple Biotech has a consensus price target of $33.00, suggesting a potential upside of 5,740.71%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer NKGN or PPBT? In the previous week, Purple Biotech had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Purple Biotech and 2 mentions for NKGen Biotech. Purple Biotech's average media sentiment score of 0.69 beat NKGen Biotech's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Purple Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, NKGN or PPBT? NKGen Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Do institutionals and insiders have more ownership in NKGN or PPBT? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, NKGN or PPBT? Purple Biotech is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen BiotechN/AN/A-$82.94M-$2.45-0.05Purple BiotechN/AN/A-$7.24M-$0.42-1.35 Is NKGN or PPBT more profitable? NKGen Biotech's return on equity of 0.00% beat Purple Biotech's return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Purple Biotech N/A -14.00%-12.52% SummaryPurple Biotech beats NKGen Biotech on 8 of the 13 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.46M$3.11B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-1.3521.4175.1826.37Price / SalesN/A240.50457.0688.69Price / CashN/A44.4425.8129.91Price / Book0.049.6113.256.28Net Income-$7.24M-$53.20M$3.29B$270.67M7 Day Performance-5.68%0.18%0.72%2.79%1 Month Performance-76.20%4.02%4.58%6.01%1 Year PerformanceN/A9.21%73.44%26.05% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.7745 of 5 stars$0.57-1.0%$33.00+5,740.7%N/A$1.46MN/A-1.3520NKGNNKGen Biotech0.1343 of 5 stars$0.15+5.3%N/A-82.9%$6.74MN/A-0.03N/AGap DownALZNAlzamend Neuro3.7945 of 5 stars$2.36+1.7%$45.00+1,806.8%-86.1%$6.72MN/A0.004Gap DownCAPSCapstone TherapeuticsN/A$1.16-1.7%N/AN/A$6.59M$44.88M0.0038CDIOCardio Diagnostics1.4679 of 5 stars$3.63-2.2%N/A-57.6%$6.54M$40K0.001VIVSVivoSim Labs0.4325 of 5 stars$2.49-0.8%N/AN/A$6.53M$140K-0.2420News CoverageACXPAcurx Pharmaceuticals2.237 of 5 stars$4.13+1.2%$31.00+650.6%-89.4%$6.47MN/A-0.393News CoverageAnalyst DowngradePMCBNuvilex1.5113 of 5 stars$1.13+20.1%N/A-45.3%$6.40MN/A0.444Gap UpHigh Trading VolumeENSCEnsysce Biosciences0.8987 of 5 stars$2.10-1.4%N/A-56.9%$6.34M$5.21M-0.5210SBFMSunshine Biopharma2.927 of 5 stars$1.41+4.1%$15.00+963.8%-46.4%$6.17M$34.87M-0.013PLRZPolyrizonN/A$1.00-2.0%N/AN/A$6.11MN/A0.00N/A Related Companies and Tools Related Companies NKGen Biotech Competitors Alzamend Neuro Competitors Capstone Therapeutics Competitors Cardio Diagnostics Competitors VivoSim Labs Competitors Acurx Pharmaceuticals Competitors Nuvilex Competitors Ensysce Biosciences Competitors Sunshine Biopharma Competitors Polyrizon Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
